Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1801-1820 of 2,251 trials

Neonatal Hypoxic Ischemic Encephalopathy: Cord Blood Stem Cell Treatment

We are studying the safety and feasibility of using a baby's own cord blood stem cells to treat neonatal hypoxic ischemic encephalopathy. The trial also looks at how this treatment may help prevent long-term neurological problems.

Neonatal Hypoxic-Ischaemic Encephalopathy>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyPediatrics

Sedation Study: Remimazolam vs. Midazolam for GI Endoscopy

We are comparing two sedation medications to see which one helps patients recover faster after upper GI endoscopy. We’ll also look at patient satisfaction and any side effects.

Healthy ParticipantsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal MedicineOtolaryngology

Kidney Cancer: New Combination Therapies

We are studying new treatment combinations for people with recurrent kidney cancer after anti-PD-(L)1 therapy. The goal is to evaluate their safety and effectiveness in improving patient responses.

Clear Cell Renal Cell Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Luspatercept for Anemia in Lower-Risk MDS Patients

We are studying whether Luspatercept can improve anemia in patients with lower-risk myelodysplastic syndromes who do not require blood transfusions. The trial will also assess its impact on quality of life and safety.

Myelodysplastic Syndromes (MDS)3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematology

Liver Cancer: Tislelizumab Immunotherapy Study

We are testing a new immunotherapy for patients with liver cancer and moderate liver function. The study aims to see if it can improve treatment outcomes and quality of life.

Hepatocellular Carcinoma (HCC)>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHepatologyOncology

Beta-Lactam Antibiotics: Precision Dosing in Critically Ill Children

We are studying a new dosing method for beta-lactam antibiotics in critically ill children to see if it helps them reach treatment goals faster than standard dosing. This may also help reduce their time in the hospital.

Systemic Infections>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesPediatrics

Urothelial Cancer: DDR Gene Testing for Chemotherapy Response

We are studying whether changes in DDR genes can help predict how well patients with advanced urothelial cancer respond to platinum-based chemotherapy. This may lead to better treatment decisions for patients based on their genetic profile.

Metastatic or Locally Advanced Urothelial Cancer1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncologyUrology

Obstructive Colon Cancer: Neoadjuvant Chemotherapy Study

We are studying whether two chemotherapy regimens can improve treatment outcomes for patients with obstructive colon cancer after colostomy. The goal is to see if starting chemotherapy before surgery leads to better recovery and survival rates.

Colon Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology

Inflammatory Disorders: New Imaging Tracer 18F-AlF-FAPI-74

We are studying a new imaging tracer to see if it can better diagnose inflammatory disorders compared to the standard tracer. This trial includes patients with fever of unknown origin, IgG4-related disease, and axial spondyloarthritis.

Fever of Unknown OriginIgG4-Related DiseaseAxial Spondyloarthritis>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesInternal MedicineOrthopedics and TraumatologyRheumatology

Pancreatic and Bile Duct Cancer: 68Ga-FAPI-46 PET Imaging Study

We are testing a new imaging method to better visualize pancreatic and bile duct cancers. This study aims to see how accurately it detects cancer and monitors treatment response.

Cholangiocarcinoma (Bile Duct Cancer)Pancreatic Carcinoma (Pancreatic Cancer)>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Bleeding Treatment in Thrombocytopenic Patients: FORMAT Study

We are studying whether adding fibrinogen to platelet transfusions helps patients with low platelet counts after chemotherapy stop bleeding. This trial will evaluate the effectiveness and safety of this treatment approach.

Blood Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematology

Friedreich Ataxia: Vatiquinone Safety Study

We are studying the long-term safety of vatiquinone in patients with Friedreich Ataxia who have previously used this medication. We aim to see how it affects their symptoms over time.

Friedreich's Ataxia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurology

Type 2 Diabetes: Personalized Treatment Study

We are exploring how different diabetes medications work for patients based on their insulin response. The goal is to find biomarkers that help tailor treatments for better management of type 2 diabetes.

Type 2 Diabetes1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyInternal Medicine

Rectal Cancer: REGorafenib and Nivolumab Treatment

We are studying a new treatment combining REGorafenib and Nivolumab with short-course radiotherapy for patients with intermediate-risk rectal cancer. The aim is to see if this approach improves treatment response and safety before surgery.

Locally-advanced Rectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Melanoma with Brain Metastases: Immunotherapy Study

We are studying the effects of immunotherapy in melanoma patients with brain metastases who are also receiving steroid treatment. Our goal is to see if this combination improves outcomes compared to standard care.

Malignant Melanoma of Skin1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Clofarabine for Advanced Urothelial Carcinoma

We are studying the safety and effectiveness of Clofarabine in patients with locally advanced or metastatic urothelial carcinoma. The trial aims to find the highest dose that can be tolerated while assessing how well the treatment works.

Bladder Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Chronic Kidney Disease: Optimizing Tacrolimus Dosage with Genetic Testing

We are studying whether a genetic testing strategy can help tailor tacrolimus dosing for patients with chronic kidney disease before kidney transplantation. This may improve treatment outcomes and reduce side effects.

Kidney Transplant1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesInternal MedicineNephrology

Activated T-Cells for Graft vs Host Disease After Stem Cell Transplant

We are testing a new treatment using activated regulatory T-cells in patients shortly after stem cell transplantation. The aim is to see if it can safely reduce the risk and severity of acute graft vs host disease.

LeukaemiaAcute graft versus host disease1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

RSV Hospitalization Prevention: Abrysvo® Vaccine Study

We are studying whether the Abrysvo® vaccine can help prevent hospitalizations from RSV in adults aged 18 and older, especially those 60 and above. This research aims to improve respiratory health outcomes in older adults.

RSV Infection6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Advanced Solid Tumors: BMS-986482 Study

We are investigating the safety and dosage of BMS-986482 alone or with other therapies for patients with advanced solid tumors. This study aims to understand how well it works in combination with existing treatments.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology